MedTrace Logo

Angiotensin II for Septic Shock Treatment

NCT03302650 · Status: SUSPENDED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2019-01-16

No results posted yet for this study

Summary

This study aims to investigate the effect of angiotensin II on microcirculation and peripheral perfusion in patients with septic shock.

Conditions

  • Septic Shock

Interventions

DRUG

Angiotensin II

Patients will receive angiotensin-II at a starting dose of 20 ng/Kg/min.

DRUG

Normal saline

Patients will receive normal saline.

DRUG

Norepinephrine

patients will receive norepinephrine infusion adjusted according to blood pressure

Sponsors & Collaborators

  • Cairo University

    lead OTHER

Principal Investigators

  • Ahmed Mukhtar, Professor · Head of research committee section in anesthesia department

  • Martin W Dünser, Professor · Department of critical care, University of London college hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-01
Primary Completion
2019-08-01
Completion
2019-08-15

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03302650 on ClinicalTrials.gov